Show simple item record

dc.contributor.authorSargent, A
dc.contributor.authorBailey, A
dc.contributor.authorTurner, A
dc.contributor.authorAlmonte, M
dc.contributor.authorGilham, C
dc.contributor.authorBaysson, H
dc.contributor.authorPeto, J
dc.contributor.authorRoberts, C
dc.contributor.authorThomson, C
dc.contributor.authorDesai, M
dc.contributor.authorMather, J
dc.contributor.authorKitchener, H
dc.date.accessioned2018-08-24T11:09:42Z
dc.date.issued2010-02
dc.identifier2
dc.identifier.citationJOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 pp. 554 - 558
dc.identifier.issn0095-1137
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2385
dc.identifier.doi10.1128/JCM.00896-09
dc.description.abstractWe present data on the use of the Hybrid Capture 2 (HC2) test for the detection of high-risk human papillomavirus (HR HPV) with different thresholds for positivity within a primary screening setting and as a method of triage for low-grade cytology. In the ARTISTIC population-based trial, 18,386 women were screened by cytology and for HPV. Cervical intraepithelial neoplasia lesions of grade two and higher (CIN2+ lesions) were identified for 453 women within 30 months of an abnormal baseline sample. When a relative light unit/cutoff (RLU/Co) ratio of >= 1 was used as the threshold for considering an HC2 result positive, 15.6% of results were positive, and the proportion of CIN2+ lesions in this group was 14.7%. The relative sensitivity for CIN2+ lesion detection was 93.4%. When an RLU/Co ratio of +/- 2 was used as the threshold, there was a 2.5% reduction in positivity, with an increase in the proportion of CIN2+ lesions detected. The relative sensitivity decreased slightly, to 90.3%. Among women with low-grade cytology, HPV prevalences were 43.7% and 40.3% at RLU/Co ratios of >= 1 and >= 2, respectively. The proportions of CIN2+ lesions detected were 17.3% and 18.0%, with relative sensitivities of 87.7% at an RLU/Co ratio of >= 1 and 84.2% at an RLU/Co ratio of >= 2. At an RLU/Co ratio of >= 1,68.3% of HC2-positive results were confirmed by the Roche line blot assay, compared to 77.2% of those at an RLU/Co ratio of >= 2. Fewer HC2-positive results were confirmed for 35- to 64-year-olds (50.3% at an RLU/Co ratio of >= 1 and 63.2% at an RLU/Co ratio of >2) than for 20- to 34-year-olds (78.7% at an RLU/Co ratio of >= 1 and 83.7% at an RLU/Co ratio of >2). If the HC2 test is used for routine screening as an initial test or as a method of triage for low-grade cytology, we would suggest increasing the threshold for positivity from the RLU/Co ratio of >= 1, recommended by the manufacturer, to an RLU/Co ratio of >= 2, since this study has shown that a beneficial balance between relative sensitivity and the proportion of CIN21 lesions detected is achieved at this threshold.
dc.format.extent554 - 558
dc.languageeng
dc.language.isoeng
dc.publisherAMER SOC MICROBIOLOGY
dc.titleOptimal Threshold for a Positive Hybrid Capture 2 Test for Detection of Human Papillomavirus: Data from the ARTISTIC Trial
dc.typeJournal Article
rioxxterms.versionofrecord10.1128/JCM.00896-09
rioxxterms.licenseref.startdate2010-02
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJOURNAL OF CLINICAL MICROBIOLOGY
pubs.notesaffiliation: Sargent, A (Reprint Author), Manchester Royal Infirm, 3rd Floor,Clin Sci Bldg,Oxford Rd, Manchester M13 9WL, Lancs, England. Desai, M.; Mather, J., Univ Manchester, Manchester Cytol Ctr, Manchester M13 9PL, Lancs, England. Roberts, C., Univ Manchester, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester M13 9PL, Lancs, England. Thomson, C.; Kitchener, H., Univ Manchester, Sch Canc & Imaging Sci, Manchester M13 9PL, Lancs, England. Almonte, M., Queen Mary Univ London, Ctr Epidemiol Math & Stat, Wolfson Inst Prevent Med, London, England. Gilham, C., Inst Canc Res, London SW3 6JB, England. Baysson, H.; Peto, J., London Sch Hyg & Trop Med, London WC1, England. keywords-plus: GRADE CERVICAL LESIONS; NATURAL-HISTORY; CANCER; WOMEN; INFECTION; ASSAY; RISK; CELL; PCR research-areas: Microbiology web-of-science-categories: Microbiology author-email: [email protected] researcherid-numbers: Almonte, Maribel/O-3286-2016 orcid-numbers: Thomson, Claire/0000-0001-9433-7779 funding-acknowledgement: United Kingdom Health Technology Assessment Programme; National Institute for Health Research [98/04/64] funding-text: The ARTISTIC trial was funded by the United Kingdom Health Technology Assessment Programme. The line blot assays were kindly provided by Roche. number-of-cited-references: 16 times-cited: 39 usage-count-last-180-days: 0 usage-count-since-2013: 1 journal-iso: J. Clin. Microbiol. doc-delivery-number: 550TB unique-id: ISI:000274151700030 oa: gold_or_bronze da: 2018-08-23
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume48en_US
pubs.embargo.termsNot known
dc.contributor.icrauthorGilham, C


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record